LYNBROOK, N.Y., Sept. 24, 2009 (GLOBE NEWSWIRE) -- IPOdesktop.com, in a continuation of its Internet radio interviews featuring BioSpecifics Technologies Corp. (Nasdaq:BSTC), today features an interview with Dr. Martin Gelbard of U.C.L.A., a board-certified and renowned urologist, and a physician consultant to BioSpecifics. Dr. Gelbard has had a key focus on the treatment of Peyronie's disease since the late 1970s, and has been affiliated with the company since that time. In the interview, Dr. Gelbard predicts that urologists worldwide will embrace the use of the company's pioneering Xiaflex injectable collagenase product in seeking better non-surgical clinical outcomes.
BioSpecifics is a biopharmaceutical company involved in the development of injectable collagenase for multiple indications. Dr. Gelbard was interviewed by IPOdesktop.com editor Francis Gaskins. The program can be accessed through the following link:
http://gaskinsco.com/bstc-mg.mp3.
In the interview, Dr. Gelbard, who was graduated from Stanford University and the University of California's Davis School of Medicine, describes how he first became aware of Peyronie's disease, which causes penile curvature and distortion, as well as psychological distress. He notes that the disease has been known for about several hundred years. But in all that time, Dr. Gelbard notes, there have been few non-surgical options available, including prescription drug therapy.
The innovative work of BioSpecifics was brought to his attention, he said, and a long term relationship ensued as the company worked to perfect its injectable product that can break down collagen material in the body.
As early as the mid-1960s, the urologist said, BioSpecifics had developed a topical collagenase ointment, and it became clear that continued development of the Xiaflex product had many potential applications.
Dr. Gelbard cited the BioSpecifics partnership with Auxilium Pharmaceuticals as the turning point in seeing the development of Xiaflex accelerate. There is a real need for non-surgical therapy, he said. The key reality is that current applications for improving clinical outcomes for Peyronie's disease are not as beneficial when compared with non-surgical treatments such as those offered by BioSpecifics, Dr. Gelbard concluded.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX(TM) product in Europe.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the ability of its partner Auxilium to obtain regulatory approval of XIAFLEX(TM) in the United States for Dupuytren's disease and Peyronie's disease, the preparedness of Auxilium for the commercial launch of XIAFLEX(TM) for the treatment of Dupuytren's disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX(TM) in its territory for these same indications, which will determine the amount of milestone, royalty and sublicense income payments it may receive; the amount of earn out payments it may receive from DFB Biotech Inc. and its affiliates; whether Auxilium exercises its option under the companies' license agreement for additional indications; the potential benefits of its existing license and development agreements; its estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company's Form 10-K for the year ended December 31, 2008 and the Form 10-Q for the quarter ended March 31, 2009 and any subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.